Trinity Biotech (TRIB) announces the next stage in realizing its comprehensive transformation plan and development of its continuous glucose monitoring technology with the appointment of Barclays Capital as its exclusive financial advisor to support its ongoing strategic realignment, reflecting the Company’s increased focus on its CGM technology as part of its broader transformation plan. With substantial progress in developing its differentiated and innovative CGM and its significant market potential, Trinity Biotech’s board and management have determined that CGM technology and related data driven insights will be the Company’s primary strategic focus moving forward. The successful execution of Trinity Biotech’s comprehensive transformation plan is expected to drive near-term profitability improvements, creating potential opportunities to optimize its portfolio and support CGM-related growth. As part of this effort, Barclays is now actively assessing how the Company’s existing businesses can best align with this new strategic direction.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRIB:
- Trinity Biotech Secures Funding for Glucose Monitoring Tech
- Trinity Biotech announces additional funding for transformation plan
- Trinity Biotech’s CGM System Shows Breakthrough Improvements
- Trinity Biotech reports findings from latest pre-pivotal trial on CGM system
- Trinity Biotech Secures Continued U.S. Government Funding for HIV Testing
Questions or Comments about the article? Write to editor@tipranks.com